Alzheimer's Disease Target Prioritization Beyond Amyloid

Neurodegeneration

Alzheimer's Disease Target Prioritization Beyond Amyloid

Neuroscience biotech needed a diversified AD target portfolio with tau-independent mechanisms for Series B diligence—within 6 weeks of investor roadshow.

Company

Series A neuroscience biotech (22-person team, AD franchise)

Timeline

March to April 2025

Engagement

Target Prioritization & Disease Mapping Pipeline

Target Prioritization & Evidence Synthesis

4 wks: Computational delivery
1,204: Targets evaluated
10: Priority targets + dossiers
7/10: Non-amyloid mechanisms

The Challenge

A Series A neuroscience biotech had committed to an amyloid-adjacent program but investors requested a diversified Alzheimer's pipeline with tau-independent and neuroinflammatory targets. Internal analysis covered only APOE pathway genes. The team needed a ranked target list with genetic evidence, blood–brain barrier (BBB) tractability, and competitive white-space analysis before a Series B roadshow in six weeks.

Business Constraints

Budget: $185K (Series A discovery budget)
Timeline: Ranked dossiers in 4 weeks
Must prioritize BBB-tractable targets suitable for small molecule modality
Exclude crowded amyloid/tau targets unless differentiated mechanism identified

TargetIQ Approach

Week 1: Multi-Omics Disease Mapping and Genetic Evidence Integration

Input

AD GWAS meta-analysis (Bellenguez et al., 2022; 111 risk loci)
Bulk and single-nucleus RNA-seq from AD cortex (ROSMAP, Mount Sinai, 8 cohorts)
Proteomic CSF biomarker datasets (MS/MS, 4 published studies)
Mendelian randomization catalog (OpenGWAS, brain-related traits)

Methods

Cross-layer evidence integration: GWAS + eQTL colocalization + expression + proteomics
Knowledge-graph GNN over neurodegeneration ontology (GO, Reactome, DisGeNET)
Cell-type deconvolution weighting (microglia, astrocyte, neuron, oligodendrocyte)
Mendelian randomization causal scoring for top 200 genes

Output

1,204-gene ranked list by AD causal relevance score
Mechanism taxonomy: amyloid (n=89), tau (n=67), neuroinflammation (n=214), metabolism (n=156), synaptic (n=198), other (n=480)
Genetic evidence heatmap for top 50 targets across 4 data layers

Week 2: BBB Tractability, Druggability, and Mechanism Diversification

BBB tractability scoring (CNS MPO predictions, P-gp substrate classification, CSF/plasma ratio from literature) filtered 1,204 to 312 CNS-accessible candidates. Druggability scoring (structure, ligand precedent, modality fit) further reduced to 78 targets. Mechanism diversification constraint enforced: maximum 3 amyloid/tau targets in Priority tier. Competitive landscape flagged 22 targets with active Phase 2+ programs. Microglia-specific single-cell weighting elevated neuroinflammatory candidates (TREM2 pathway, complement cascade, lipid metabolism).

Week 3–4: Dossier Assembly and Investor-Ready Package

Output

Top 10 priority targets with full evidence dossiers and mechanism classification
24-target expanded list across 5 mechanism classes
BBB tractability report per target with MPO score and P-gp liability
Competitive white-space matrix (target × modality × phase)
Series B diligence appendix: target rationale, risk tiers, validation roadmap
Recommended biomarker strategy per target (CSF, PET, plasma)

Diversified AD Target Portfolio

Top 10 targets with mechanism class, BBB score, and evidence dossiers. Amyloid/tau capped at 3 in priority tier per client constraint.

Ranked AD targets by causal evidence, BBB tractability, and competitive white-space
Rank	Target	Mechanism	BBB Score	Druggability	Status
1	TREM2	Microglia / innate immunity	0.82	0.76	Priority A
2	ABCA7	Lipid metabolism / phagocytosis	0.79	0.68	Priority A
3	SPI1 (PU.1)	Microglial transcription	0.71	0.62	Priority A (novel)
4	CLU (ApoJ)	Chaperone / Aβ clearance	0.88	0.74	Priority A
5	INPP5D (SHIP1)	Microglial signaling	0.75	0.70	Priority B
6	SORL1	Endosomal trafficking	0.84	0.72	Priority B
7	CR1	Complement / inflammation	0.69	0.65	Priority B
8–10	Mixed (incl. PLCG2, HLA-DRA)	Neuroinflammation / immune	0.65–0.80	0.60–0.73	Priority B/C

Results and impact

Speed, validation, and business outcomes

Speed vs. Internal Amyloid-Focused Analysis

Metric	Internal Analysis	TargetIQ	Improvement
Timeline	3+ months (part-time FTE)	4 weeks	3× faster
Cost	$280K (FTE + CRO bioinformatics)	$185K	34% savings
Targets Evaluated	~80 (APOE pathway only)	1,204 (multi-omics + MR)	15× broader search
Mechanism Diversity	Amyloid-centric	7/10 non-amyloid priority targets	Investor-ready diversification
Investor Package	Slide deck (internal)	10 dossiers + diligence appendix	Due-diligence ready

Series B Diligence Validation (6 weeks post-delivery)

Investor scientific advisory board review and literature cross-check.

Target	Mechanism	Independent Evidence	Investor Rating	Notes
TREM2	Microglia	Strong (GWAS + functional)	High conviction	Differentiated from anti-amyloid; BBB dossier cited
ABCA7	Lipid metabolism	Strong (GWAS + MR)	High conviction	White-space confirmed; no Phase 2 small molecules
SPI1	Microglial TF	Moderate (scRNA + MR)	Exploratory	Novel; investors requested validation plan in dossier
CLU	Chaperone	Strong (GWAS + proteomics)	Moderate	Known biology; differentiated modality angle in dossier
INPP5D	Microglial signaling	Moderate (GWAS)	Moderate	Backup tier; strong genetic signal
Rank 6–10	Mixed	Moderate	4/5 accepted as pipeline options	Portfolio breadth cited in term sheet

7/10: Non-amyloid/tau priority targets
8/10: Targets with GWAS + expression concordance
$42M: Series B closed (target portfolio cited)
4 wks: Time from brief to investor-ready dossiers

Immediate Wins

Series B closed at $42M: lead investor cited diversified target portfolio as key diligence differentiator
Mechanism diversification satisfied investor requirement for non-amyloid pipeline depth
BBB tractability pre-filter eliminated 892 targets with predicted CNS access liability before investor review
Diligence appendix adopted verbatim into data room; reduced follow-up Q&A cycle by 3 weeks

Strategic Advantages

Mendelian randomization scoring elevated ABCA7 and SPI1 above expression-only internal candidates
Microglia single-cell weighting aligned portfolio with 2024–2025 neuroinflammation investment thesis
Competitive white-space matrix identified ABCA7 and INPP5D as targets with strong genetics but no Phase 2 small-molecule programs
Mechanism taxonomy enabled board-level portfolio visualization beyond single-program narrative

Follow-on engagement
Q3 2025: TREM2 small molecule feasibility engagement. Estimated cost: $95K. Target: druggability deep-dive + structural assessment within 2 weeks.

Model validation

Lessons and recommendations

What Worked

Multi-layer genetic evidence (GWAS + MR + colocalization) was primary investor confidence driver
BBB scoring prevented inclusion of biologically strong but CNS-inaccessible targets (saved 2 embarrassing diligence questions)
Mechanism cap (max 3 amyloid/tau) forced portfolio diversification and improved investor narrative
CSF proteomics integration upgraded CLU and SORL1 rankings vs. transcriptomics-only analysis

Challenges and Mitigations

SPI1 (transcription factor) scored low on traditional druggability (0.62) due to intracellular nuclear target class.

Mitigation: Dossier included modality expansion analysis (PROTAC, molecular glue, gene therapy) with precedent cases; flagged as modality-differentiated opportunity.

TREM2 had emerging competitive activity (Alector Phase 2, Denali Phase 1) threatening white-space narrative.

Mitigation: Competitive brief differentiated by modality (small molecule vs. antibody) and epitope/mechanism angle; investors accepted differentiated entry rationale.

When to use TargetIQ for neurodegeneration target prioritization

Investor diligence or Series B/C requiring diversified target portfolio beyond single mechanism
Franchise expansion into AD, PD, or ALS needing causal evidence synthesis
Need for BBB tractability and CNS druggability integrated with genetic evidence
Internal analysis limited to single pathway (amyloid, tau, or APOE) without multi-omics breadth

ROI: approximately 12:1 ($42M Series B enabled vs. $185K engagement; timeline compression avoided 2-month fundraising delay).

Next steps: advance TREM2 and ABCA7 to hit-finding feasibility; ingest client iPSC-derived microglia RNA-seq for SPI1 validation.

About This Engagement

Client profile: Series A neuroscience biotech, 22 employees, AD-focused
Project duration: 4 weeks (computational delivery) + 6 weeks (investor diligence)
Total cost: $185K
Date: March to April 2025

This case study is anonymized at client request. Target names are published biology; fundraising details rounded at client request. Full dossiers available under NDA.

Run a similar program with TargetIQ.

Tell us about your target. We will scope a 2 to 4 week pilot.

Schedule a Consultation [email protected]